Handelsavisen
prelaunch
Companies Healthcare NLH.V
NL
NLH.V TSX Venture Healthcare Facilities & Services

Nova Leap Health Corp

$0,38
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
3,4 %
ROE
2,6 %
Net margin
7,4 %
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Nova Leap Health Corp operates in the healthcare sector, providing pharmaceutical services and equipment, and generates revenue primarily through its healthcare facilities and services.

Business. Nova Leap Health Corp (NLH.V) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Nova Leap Health Corp is headquartered in Canada and is listed on the TSX Venture Exchange. Specific details regarding operating segments and geographic breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
2,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NLH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NLH.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nova Leap Health Corp (NLH.V) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Nova Leap Health Corp is headquartered in Canada and is listed on the TSX Venture Exchange. Specific details regarding operating segments and geographic breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Nova Leap Health Corp maintains a relatively strong liquidity position, with a current ratio of 1.78, indicating the company can cover its short-term liabilities with its short-term assets. The company's cash and equivalents amount to $1,116,760, while its long-term debt is $1,248,940, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.07 suggests a conservative capital structure with minimal leverage.

    In terms of profitability, the company's return on equity (ROE) is 2.59%, and its return on assets (ROA) is 2.27%, both of which are below the industry median for healthcare facilities and services. The operating margin is 3.36%, and the net profit margin is 7.35%, indicating that the company is generating a modest profit relative to its revenue.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to regional economic or regulatory risks.

    The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. The capital expenditure for the period is reported as $0, suggesting that the company is not currently investing in new physical assets.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to fund operations without external financing. The dilution risk is low, and there are no significant adjustments applied to the valuation metrics.

    Recent events, such as analyst estimates, show that the last actual EPS was -$0.01, and the last actual revenue was $35,325,000. These figures suggest that the company is currently reporting a small loss per share, which may impact investor sentiment and stock performance.

    Key takeaways
    • Nova Leap Health Corp has a conservative capital structure with a low debt-to-equity ratio of 0.07.
    • The company's ROE and ROA are below the industry median, indicating lower profitability relative to peers.
    • The company's liquidity is moderate, with a current ratio of 1.78, but its net cash position is negative after subtracting total debt.
    • The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.
    • The company is not currently investing in new physical assets, as indicated by a capital expenditure of $0.
    • The company's recent financial performance shows a small loss per share, which may affect investor confidence.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew 32.5% year-over-year to $31.5 million in fiscal 2024, demonstrating strong top-line expansion momentum.

    Operating income improved to $981,700 in fiscal 2024, indicating successful operational efficiency gains despite revenue growth.

    The debt-to-equity ratio of 0.07 is well below the cohort median of 0.32, suggesting a conservative capital structure.

    Gross profit increased to $12.5 million in fiscal 2024, reflecting improved cost management or pricing power.

    BEAR CASE · 1

    Long-term debt increased to $2.9 million in fiscal 2024, rising from $2.5 million in the previous year.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2024-03-07
    Q4 2023 · Quarter highlights

    Revenue $8.3M, +29,0% YoY; Operating income +308,7% YoY.

    Revenue$8.3M+29,0 % YoY
    Operating income$375.4k+308,7 % YoY
    Net income$426.2k+305,0 % YoY
    Free cash flow$659.6k+1 169,0 % YoY
    EPS
    Operating cash flow$1.3M+21,9 % YoY
    Financials
    Income statement
    Revenue$8.3M
    Gross profit$3.3M
    Operating income$375.4k
    Net income$426.2k
    Margins
    Gross margin39.6%
    Operating margin4.5%
    Net margin5.2%
    FCF margin8.0%
    Balance sheet
    Total assets$23.6M
    Total liabilities$4.8M
    Total equity$18.8M
    Cash & equivalents$1.6M
    Long-term debt$3.0M
    Cash flow
    Operating cash flow$1.3M
    CapEx
    Free cash flow$659.6k
    SBC
    P&L flow · revenue → net income
    Revenue $8.3MOperating costs $7.9MNet income $426.2k
    Highlights
    • Revenue $8.3M, +29,0% YoY
    • Operating income +308,7% YoY
    • Net income +305,0% YoY
    • Free cash flow +1 169,0% YoY
    • Net margin 5.2%

    Valuation TTM

    Market price
    $0,38
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $18.3M
    Net cash
    -$132.2k
    Current ratio
    1.8
    Debt / equity
    0.1
    ROA
    2.3%
    ROE
    2.6%
    Cash conversion
    79.0%
    CapEx / revenue
    0.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin3,4 %Below median
    Net Margin7,4 %Above median
    ROE2,6 %Below median
    Capex / Rev0,0 %Above P75
    D/E0,07Above P75
    Cash Conv0,79Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Nova Leap Health Corp Market data — financials · 2026-05-28
    • Nova Leap Health Corp Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Chris Donald DobbinPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NLH.VCanonical
    TSX Venture · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-03-07 18:01 UTCEARNINGSQuarterly results — Q4 2023 Revenue USD 8.3M · Net USD 0.4M
    2024-03-07 18:01 UTCEARNINGSAnnual results — FY 2024 Revenue USD 31.5M · Net USD -0.2M
    2023-11-09 11:03 UTCEARNINGSQuarterly results — Q3 2023 Revenue USD 8.0M · Net USD -0.5M
    2023-08-10 17:10 UTCEARNINGSQuarterly results — Q2 2023 Revenue USD 7.1M · Net USD -0.1M
    2023-05-11 18:00 UTCEARNINGSQuarterly results — Q1 2023 Revenue USD 6.6M · Net USD 0.9M
    2023-03-08 17:33 UTCEARNINGSQuarterly results — Q4 2022 Revenue USD 6.4M · Net USD -0.2M
    2023-03-08 17:33 UTCEARNINGSAnnual results — FY 2023 Revenue USD 25.8M · Net USD 1.4M
    2022-11-10 17:18 UTCEARNINGSQuarterly results — Q3 2022 Revenue USD 6.3M · Net USD 0.2M
    2022-08-12 08:35 UTCEARNINGSQuarterly results — Q2 2022 Revenue USD 6.4M · Net USD 0.5M
    2022-03-10 17:01 UTCEARNINGSAnnual results — FY 2022 Revenue USD 26.2M · Net USD -1.1M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage